Aurobindo Pharma (ARBP) would acquire seven marketed oncology products, intellectual property and commercial infrastructure from Spectrum Pharma for a consideration of USD300m, which includes an upfront payment of USD160m and a milestone-linked payment of USD140m.
For 2QFY2019, Aurobindo Pharma (APL), the company posted sales of Rs. 4,667cr v/s. Rs. 4,354cr in 2QFY2018, a yoy growth of 7.2%. On the operating front, the EBITDA margin came in at 18.8% v/s. 23.8% in 2QFY2018.
Aurobindo Pharma’s (APL) acquisition of Sandoz’s product portfolio (dermatology and oral solids) for US$900mn will fetch a similar amount in incremental sales (30% from dermatology products and the rest from oral solids) in the first full year post transaction closure (six to nine months from the announcement).
This is neither an offer nor a solicitation to purchase or sell securities. The information and views contained on this site are believed to be reliable, but no responsibility (or liability) is accepted for errors of fact or opinion. Writers and contributors may be trading in, or have positions in the securities mentioned in their articles. Neither IndiaNotes nor any of the contributors accepts any liability arising out of use of the above information/article. Reproduction in whole or in part without written permission is prohibited.